This website uses cookies. By using the site you are agreeing to our Privacy Policy.

Suomi

New production facility at FUJIFILM Manufacturing Europe B.V.

Fujifilm will produce cell culture media for biopharmaceutical industry in Tilburg

02.07.2019

FUJIFILM Manufacturing Europe B.V. announced plans to build a new production facility on the site in Tilburg. In June 2018, FUJIFILM Corporation acquired the company, current FUJIFILM Irvine Scientific, Inc., which has been a worldwide leader in the development and manufacturing of cell culture media since 1970 and has currently sites in the United States and Japan. There is need to expand in Europe with a third manufacturing facility and this will be built in Tilburg.

A factory of Fujifilm will be transformed to a manufacturing facility for the production of cell culture media used at biopharmaceutical industry. The products, solid and liquid, will be produced according the requirements of the quality assurance system cGMP (current Good Manufacturing Practice), required by, among others, the pharmaceutical industry.

Cell culture media deliver nutrients for cells to grow. President Peter Struik:

The production of cell culture media is a highly technical and difficult process that requires precision engineering and a commitment to quality. At Fujifilm we possess production expertise, the facilities and a good infrastructure. This was a good combination and we are pleased to contribute to biopharmaceutical industry through providing high quality products.

Work on the manufacturing site has begun and it is expected to be commissioned in the second half of 2021. We expect it will provide 50 to 70 jobs.

The biopharmaceutical market is growing at a high rate. The current capacity FUJIFILM Irvine is >1,000,000 Kg/year of dry powder, but it is imperative that we exceed production requirements of customers worldwide, as well as meet our European customer demand for regional support,

said Yutaka Yamaguchi, CEO, FUJIFILM Irvine Scientific.

Building a third, world-class cGMP manufacturing facility to serve as a European hub will enable us to better provide customers with rapid, reliable supply of products.

Tuoreimmat uutiset:
  • Company
  • Corporate
  • Healthcare